Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tuparstobart by Incyte for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Tuparstobart is under clinical development by Incyte and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
INCB-099280 by Incyte for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to...
Tuparstobart by Incyte for Solid Tumor: Likelihood of Approval
Tuparstobart is under clinical development by Incyte and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Parsaclisib by Incyte for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Parsaclisib is under clinical development by Incyte and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
Parsaclisib by Incyte for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Parsaclisib is under clinical development by Incyte and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
Verzistobart by Incyte for Merkel Cell Carcinoma: Likelihood of Approval
Verzistobart is under clinical development by Incyte and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData, Phase...
Itacitinib adipate by Incyte for Hairy Cell Leukemia: Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Hairy Cell Leukemia. According to GlobalData,...
Itacitinib adipate by Incyte for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...
Povorcitinib phosphate by Incyte for Chronic Urticaria Or Hives: Likelihood of Approval
Povorcitinib phosphate is under clinical development by Incyte and currently in Phase II for Chronic Urticaria Or Hives. According to...
Itacitinib adipate by Incyte for Cytokine Release Syndrome (Cytokine Storm): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Cytokine Release Syndrome (Cytokine Storm). According...
INCB-099280 by Incyte for Gynecological Cancer: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Gynecological Cancer. According to GlobalData, Phase II...
INCB-099280 by Incyte for Metastatic Colorectal Cancer: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
INCB-099280 by Incyte for Renal Cell Carcinoma: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...
INCB-099280 by Incyte for Metastatic Melanoma: Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
INCB-099280 by Incyte for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
INCB-099280 is under clinical development by Incyte and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
INCA-033989 by Incyte for Essential Thrombocythemia: Likelihood of Approval
INCA-033989 is under clinical development by Incyte and currently in Phase I for Essential Thrombocythemia. According to GlobalData, Phase I...
INCA-033989 by Incyte for Myelofibrosis: Likelihood of Approval
INCA-033989 is under clinical development by Incyte and currently in Phase I for Myelofibrosis. According to GlobalData, Phase I drugs...
Pemigatinib by Incyte for Non-Small Cell Lung Cancer: Likelihood of Approval
Pemigatinib is under clinical development by Incyte and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Incyte's Axatilimab?
Axatilimab is a monoclonal antibody commercialized by Incyte, with a leading Pre-Registration program in Graft Versus Host Disease (GVHD). According...
Risk adjusted net present value: What is the current valuation of Incyte's Povorcitinib?
Povorcitinib is a small molecule commercialized by Incyte, with a leading Phase III program in Hidradenitis Suppurativa. According to Globaldata,...